TP53 is mutated in 20-25% of aggressive B-cell lymphoma (B-NHL). To date, no studies have addressed the impact of TP53 mutations in prospective clinical trial cohorts. To evaluate the impact of TP53 mutation to current risk models in aggressive B-NHL, we investigated TP53 gene mutations within the RICOVER-60 trial. Of 1,222 elderly patients (aged 61-80 years) enrolled in the study and randomized to six or eight cycles of CHOP-14 with or without Rituximab (NCT00052936), 265 patients were analyzed for TP53 mutations. TP53 mutations were demonstrated in 63 of 265 patients (23.8%). TP53 mutation was associated with higher LDH (65% vs. 37%; p < 0.001), higher international prognostic index-Scores (IPI 4/5 27% vs. 12%; p 5 0.025) and B-symptoms (41% vs. 24%; p 5 0.011). Patients with TP53 mutation were less likely to obtain a complete remission CR/CRu (CR unconfirmed) 61.9% (mut) vs. 79.7% (wt) (p 5 0.007). TP53 mutations were associated with decreased event-free (EFS), progression-free (PFS) and overall survival (OS) (median observation time of 40.2 months): the 3 year EFS, PFS and OS were 42% (vs. 60%; p 5 0.012), 42% (vs. 67.5%; p < 0.001) and 50% (vs. 76%; p < 0.001) for the TP53 mutation group. In a Cox proportional hazard analysis adjusting for IPI-factors and treatment arms, TP53 mutation was shown to be an independent predictor of EFS (HR 1.5), PFS (HR 2.0) and OS (HR 2.3; p < 0.001). TP53 mutations are independent predictors of survival in untreated patients with aggressive CD201 lymphoma. TP53 mutations should be considered for risk models in DLBCL and strategies to improve outcome for patients with mutant TP53 must be developed.
Introduction
Molecular disease markers such as the cell of origin classification (activated B-cell vs. germinal center B-cell (ABC/GCB), 1 chromosomal translocations, 2 immunohistochemical markers [3] [4] [5] and gene mutations define important molecular subgroups in diffuse large B-cell lymphoma (DLBCL). 6, 7 Current risk models in DLBCL include clinical scores (IPI) 8 while molecular markers are less firmly embedded into routine clinical care. In part, this is due to the fact that few studies have demonstrated a beneficial impact of molecular markers in clinical trials or on (stratified) treatment decisions. While precision medicine approaches will enter care of patients with aggressive lymphoma e.g. by targeting b-cell receptor (BCR) pathway alterations 9 or gene mutations, 10 it will also be important to identify high-risk subgroups unlikely to be cured by R-CHOP early on.
The negative prognostic impact of TP53 mutations in DLBCL has been reported in a number of studies. [11] [12] [13] Most studies have identified TP53 mutations in 20-25% of DLBCL cases, with a similar incidence in GCB and ABC subtypes, 14 which suggests that TP53 mutation is the most frequent gene mutation common to both GCB and ABC subtypes. 6 TP53 mutation has also been shown to impact survival of patients e.g. with primary central nervous system lymphoma. 15 A recent large cooperative study of 506 patients treated with R-CHOP found mutations in 21.9% and showed that patients whose tumors harbored TP53 mutations had worse overall and progression-free survival (PFS). 16 TP53 mutation was of prognostic impact for R-CHOP-treated patients with both germinal center and activated B-cell DLBCL subtypes. In addition, mutations of loop-sheet-helix and L3 motifs in the DNA-binding domain have been suggested to be the most critical structures for maintaining p53 function based on a subgroup analysis. 16 Notwithstanding these comprehensive data sets, heterogeneity of cohorts and studies outside of controlled clinical trials has precluded a precise definition of the role of the TP53 mutation and integration into routine work-up of patients with aggressive B-NHL.
In an effort to evaluate the prognostic impact of TP53 mutations in relation to treatment and clinical as well as molecular characteristics, we analyzed an aggressive B-NHL trial cohort (RICOVER 60 trial). 17 Our findings suggest TP53 mutation as an important prognostic factor in aggressive B-NHL independent of treatment. Mutation analysis of TP53 should be incorporated into prognostic models in DLBCL. Stratified treatment trials for patients with TP53 mutant DLBCL are needed to improve outcome of these patients.
Methods

Patients and samples
All cases analyzed in our study had been enrolled in the prospective randomized multicenter clinical RICOVER-60 trial of the DSHNHL in which patients 60-80 years with CD20-positive aggressive B cell lymphomas were randomized to 6 or 8 cycles of CHOP-14 with or without addition of 8 cycles rituximab. 17 Radiotherapy was planned to sites of initial bulky disease and to sites of extranodal involvement. Between July 1, 2000 and June 14, 2005, 1,242 patients were enrolled in 203 institutions. The primary endpoint was event-free survival (EFS); secondary endpoints were rates of response, progression during treatment, PFS, overall survival (OS) and frequency of toxic effects. Analyses were done by intention to treat. This clinical trial was conducted in accordance with the Helsinki declaration and the protocol had been approved by the ethics review committee of each participating center.
TP53 sequencing
Sanger sequencing was used to identify samples containing mutations in exons 5-9 (DNA binding region of TP53). Two hundred and sixty-five patients with aggressive B-NHL where sufficient DNA was available were studied, and these were representative for the whole cohort with regard to sex, age, ECOG, stage, extranodal disease, cumulative IPI and rituximab arm (Supplemental Table S1 and S2). All samples were sequenced by automated fluorescent sequencing using the Big Dye Terminator Kit and an ABI 3100 sequencer (Applied Biosystems, Foster City, USA). The mutations had to be confirmed by sequencing in both directions and repeated PCRs to reduce sequencing error. The primers were designed to cover exons and intron-exon boundaries.
Histopathological diagnosis, FISH analysis and immunohistochemistry
Samples of diagnostic biopsies of trial patients were reviewed by expert hematopathologists and diagnoses were rendered according to the WHO classification. 18, 19 Fluorescence in situ hybridization (FISH) analyses targeting BCL2, BCL6 and MYC loci, and immunohistochemistry had been performed as reported previously. 3, 5 p53 immunohistochemistry was performed on TMAs using the DAKO Antibody DO7 (DAKO, Glostrup, Denmark), where samples were available. The number of strongly positive tumor cell nuclei was recorded by increments of 10%.
Statistical analysis
EFS was defined as the time from the start of therapy to disease progression, relapse, death or initiation of additional (off-protocol) or salvage therapy. PFS was defined as time to disease progression, relapse or death. OS was defined as time to death for any reason. EFS, PFS and OS were estimated using the Kaplan-Meier method, and compared using the log-rank test. Display of all Kaplan-Meier curves was stopped at 60 months of follow-up due to the low number of patients What's new? Personalized medicine will soon improve treatment for many cancers. However, it's also important to identify high-risk subgroups that are unlikely to be cured with current therapies. In this study, the authors found that mutations in the TP53 gene may help predict the survival of patients with aggressive B-cell lymphomas, regardless of treatment. TP53 mutations should thus be included as a prognostic biomarker in the development and assessment of risk models for B-cell non-Hodgkin lymphoma.
at risk after 60 months. In addition, prognosis of subgroups was quantified by 3-year survival with 95% confidence intervals. Median follow-up was 40.2 months for patients included in our study. Statistical significance was defined as p < 0.05. Analysis was performed using statistic software R (version 3.0.1. 
Results
Incidence TP53 mutations were demonstrated in tumors from 63/265 (24%) patients analyzed.
A complete list of mutations is provided in Supplemental  Table S1 . Most patients had single mutations (n 5 60), but 4 had 2 or more mutations (total number of mutations: 69) (Supplemental Table 3 ). As previously reported, missense mutations were most common (50/69; 72.4%).
We analyzed the association of TP53 mutations with clinical characteristics: Table 1 summarizes the comparison of the clinical and genomic profiles of aggressive B-NHL with and without TP53 mutation. TP53 mutation was associated with 
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elevated LDH (65% vs. 37%: p < 0.001), higher IPI-Scores (IPI 4/5 27% vs. 12%; p 5 0.025) and B-symptoms (41% vs. 24%; p 5 0.011) (TP53 mutant (mut) and wild type (wt) groups respectively). There was a borderline association with bulky disease (46% vs. 33%; p 5 0.07). TP53 mutations were independent of overexpression of BCL2, BCL6 and MYC protein, and were not associated with GCB/non-GCB type as defined by the Hans classifier. Likewise, no significant association was seen with immunoblastic morphology, nor rearrangements of BCL2, BCL6 or MYC. However, we confirm a strong correlation with p53 overexpression in >25% of cells and TP53 mutation (Fisher's exact <0.001) ( Table 1) .
Survival of patients with TP53 mutation
To assess the impact of TP53 mutations on outcome of elderly patients with aggressive B-NHL, we assessed response, EFS, PFS and OS according to the presence or absence of TP53 mutations. Response to both CHOP and R-CHOP treatments was significantly inferior in patients with TP53 mutation, where 39/63 (62%) patients achieved CR or CRu in contrast with 161/202 (80%) with wt TP53 (p 5 0.007; Table 2 ). At 36 months, 67.5% of patients without TP53 mutation were free from progression. In contrast, in the group with TP53 mutation only 42% were progression free (p < 0.001). Similarly, EFS was significantly shorter for TP53 mutant NHL cases: the 3-year event-free fraction was 42% in mutant vs. 60% for patients with wild type (p 5 0.012) (Fig. 1a) .
The OS of patients with TP53 mutation was 50% at 3 years vs. 76% for patients without TP53 mutation (p < 0.001) (Fig. 1b) .
TP53 mutation and treatment effect
To assess a potential treatment effect across treatment arms of the trial (63 vs. 83 CHOP; R vs. no R) within the subgroups defined by TP53 mutation, we studied the impact of treatment stratified for TP53 status. TP53 mutation impacted both EFS and OS in all treatment comparisons (Figs. 2ad) . There was no difference in the treatment arms for EFS and OS in patients with mutant TP53, suggesting that alternative treatments need to be explored in this subgroup (Figs. 3a  and 3b ). For patients with wt TP53, overall outcome was favorable and the addition of R but not the number of treatment cycles had an impact on EFS (Fig. 3c) . OS showed a similar trend indicating favorable outcome for wt TP53 patients treated with R-CHOP (Fig. 3d ).
Multivariate models of prognostic factors
To assess if TP53 mutation was an independent prognostic factor, we generated multivariate Cox models adjusting for individual IPI factors, TP53 mutation status and treatment arms. Sample size and missing values precluded the use of a multivariate model including additional molecular features (IHC, FISH (BCL2, BCL6, MYC)). Independent factors for PFS were rituximab treatment (HR 0.48; p < 0.001), elevated LDH (HR 1.90, p 5 0.003), ECOG (HR 1.86, p 5 0.016), stage (HR 2.22, p < 0.001) and TP53 mutation (HR 2.04, p 5 0.001) ( Table 3) . Independent factors for OS were TP53 mutation (HR 2.25, p < 0.001), LDH (HR 1.93, p 5 0.007), ECOG (HR 2.08, p 5 0.009) and stage (HR 2.02, p 5 0.007). Addition of rituximab or number of treatment cycles was not significant in the Cox model for OS (Table 3 ).
Discussion
Our study aimed to optimize risk models in aggressive B NHL by studying TP53 mutations in patients enrolled into the randomized RICOVER-60 1st line treatment trial comparing CHOP (6 vs. 8 cycles) and the addition of rituximab treatment. We were able to analyze a representative cohort of 265 of 1,222 included patients. With mature follow-up, we The OS of patients with TP53 mutation was poor with a 3-year survival of 50% (38.6-64.7%) (n 5 63; gray line) compared to 76.1% (69.7-83.1) for patients with wild type TP53 (Log rank test: p < 0.001).
found independent prognostic impact of TP53 mutations on EFS, PFS and OS in multivariate analyses. Based on these data, strategies to improve outcome for the 20-25% of patients with aggressive B-NHL and mutant TP53 should be developed as CR rate was shown to be only 62% and EFS at 3 years was 42%. The 3-year OS of patients with aggressive B-NHL was estimated at 50%, which was independent of treatment arm. While the incidence of TP53 mutations is in line with prior studies, Sanger sequencing -while the recommended technique per guidelines in CLL 20 -has a lower sensitivity than e.g. next-generation sequencing approaches. It is foreseeable that use of more sensitive technology could increase the proportion of patients shown to harbor TP53 mutations as demonstrated in CLL.
21
TP53 mutations have been associated with poor prognosis in a number of cancers, among them breast cancer, head and neck cancer and malignant lymphoma, CLL, AML. 22 The clinical effect of TP53 mutations within the latter group of malignancies appears to be particularly profound in CLL, probably explainable by growth kinetics as a major determinant of chemotherapy response and cure rate in lymphoma. The detection of TP53 mutations has been associated with poorer prognosis in DLBCL. 13, 16, 22, 23 Our analysis of TP53 mutant cases shows that outcome of this group is poor even if R-CHOP is given, suggesting that TP53 testing should be integrated into risk models in DLBCL and patients with TP53 mutations may be prime candidates for novel approaches in clinical trials. We show, that TP53 mutation and p53 protein overexpression are related, while they are not associated with factors such as immunoblastic morphology, neither MYC or BCL2 translocation status, nor MYC and BCL2 protein 
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overexpression even though individual subgroups are small. 3, 5 This independence is in contrast to more recent reports that observed that the dual overexpression of p53 protein together with MYC rearrangement or overexpression may denote a patient group with poor clinical outcome comparable to patients whose tumors exhibit a dual MYC and BCL2 deregulation (the so-called double hit or double expressor lymphomas. 24, 25 We were not able to find similar associations in our study cohort, however, the statistical power for the analysis was limited due to the small number of only 17 patients with MYC translocation (Table 1) . XuMonette et al. highlighted the importance of concomitant TP53 mutation and p53 protein expression analysis in the assessment of prognosis, and found that p53 (and also MDM2) overexpression was associated with shorter survival only in TP53 mutated, but not wild type, DLBCL. 26 In our cohort only 3/118 (2.5%) patients with wild type TP53 showed p53 overexpression, suggesting that the effect of overexpression is tightly associated with mutation of TP53.
Based on the similarity of treatment approaches for the cohort described and patients younger than 60, our data can be expected to apply to all patients with aggressive B-NHL, but formal proof should emerge from current sequencing efforts in trial cohorts. The analysis of a randomized trial cohort allowed us to assess the impact of TP53 mutation within the different treatment arms. The data suggest that neither addition of R nor cycle number as a way of treatment intensification impact outcome within the group of patients with mutant TP53. It is currently unclear if high-dose treatments would improve the outcome of this high-risk group. Data from mantle cell lymphoma suggest that intensification of chemotherapy does not improve outcome of MCL with TP53 deletion (17p deletion). 27 For the design of future trials for this high-risk subgroup of patients it will be important to develop both nongenotoxic combinations as well as improved models predicting outcome. This will also include the consideration of further molecular markers such as methylation changes 28, 29 and other recurrent gene mutations as recently suggested for follicular lymphoma. 30 While we provide evidence that TP53 mutations are associated with very poor survival, 50% of patients with mutant TP53 are cured with CHOP, a finding which provides evidence for more complex genotype-phenotype associations.
In summary, our findings show that TP53 mutations are associated with poor prognosis independent of treatment in elderly patients with aggressive B-NHL. The integration of TP53 mutation testing into care and trials for aggressive B-NHL patients will identify a 20-25% subgroup of patients who are prime candidates for novel combinatorial treatments and trials.
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